Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7128665rdf:typepubmed:Citationlld:pubmed
pubmed-article:7128665lifeskim:mentionsumls-concept:C0028426lld:lifeskim
pubmed-article:7128665lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:7128665lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:7128665pubmed:issue6lld:pubmed
pubmed-article:7128665pubmed:dateCreated1982-12-16lld:pubmed
pubmed-article:7128665pubmed:abstractTextNoscapine was administered to five healthy volunteers in a randomized crossover design, as an intravenous infusion of 66 mg, and as an oral 150 mg dose of either rapidly dissolving tablets or a tablet containing ion exchange resin-bound noscapine. After i.v. administration, the disposition of noscapine was bi-exponential with an elimination half-life of 2.6 h; the total plasma clearance was 22 ml/min/kg and the volume of distribution (Vdarea) was 4.7 l/kg. The absolute oral bioavailability was 30%, with a 3.6-fold interindividual variation. There was no pharmacokinetic evidence to support a prolonged action of the ion exchange resin tablet.lld:pubmed
pubmed-article:7128665pubmed:languageenglld:pubmed
pubmed-article:7128665pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7128665pubmed:citationSubsetIMlld:pubmed
pubmed-article:7128665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7128665pubmed:statusMEDLINElld:pubmed
pubmed-article:7128665pubmed:issn0031-6970lld:pubmed
pubmed-article:7128665pubmed:authorpubmed-author:JohanssonMMlld:pubmed
pubmed-article:7128665pubmed:authorpubmed-author:DahlströmBBlld:pubmed
pubmed-article:7128665pubmed:authorpubmed-author:MellstrandTTlld:pubmed
pubmed-article:7128665pubmed:authorpubmed-author:LöfdahlC GCGlld:pubmed
pubmed-article:7128665pubmed:issnTypePrintlld:pubmed
pubmed-article:7128665pubmed:volume22lld:pubmed
pubmed-article:7128665pubmed:ownerNLMlld:pubmed
pubmed-article:7128665pubmed:authorsCompleteYlld:pubmed
pubmed-article:7128665pubmed:pagination535-9lld:pubmed
pubmed-article:7128665pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:meshHeadingpubmed-meshheading:7128665-...lld:pubmed
pubmed-article:7128665pubmed:year1982lld:pubmed
pubmed-article:7128665pubmed:articleTitlePharmacokinetic properties of noscapine.lld:pubmed
pubmed-article:7128665pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7128665pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7128665pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7128665lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7128665lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7128665lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7128665lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7128665lld:pubmed